BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early ‐Stage Parkinson's Disease

ConclusionsGenotyping for the rs6265 polymorphism may be useful for predicting long-term response to drug therapy and counseling Parkinson's disease patients regarding whether to consider earlier subthalamic nucleus deep brain stimulation. Validation in a larger cohort of early-stage Parkinson's disease subjects is warranted.

Source: Neuromodulation: Technology at the Neural Interface - July 20, 2021 Category: Biotechnology Authors: Caryl E. Sortwell, Mallory L. Hacker, David Luke Fischer, Peter E. Konrad, Thomas L. Davis, Joseph S. Neimat, Lily Wang, Yanna Song, Zach R. Mattingly, Allyson Cole ‐Strauss, Jack W. Lipton, P. David Charles Tags: Clinical Research Source Type: research